Pharm
Finerenone
search
Finerenone
, Kerendia
See Also
Aldosterone Antagonist
Diabetic Nephropathy
Indications
Diabetic Nephropathy
(Type 2 Diabetes)
May limit renal fibrosis and inflammation and may decrease CKD progression (in combination with ACE or ARB)
Contraindications
eGFR <25 ml/min (increased risk of
Hyperkalemia
)
Serum Potassium
> 5.0 mmol/L (at time of starting medication)
Mechanism
Non-Steroidal
Aldosterone Antagonist
(mineralcorticoid receptor
Antagonist
)
Similar anti-
Aldosterone
effects of steroidal
Aldosterone Antagonist
s (
Eplerenone
,
Spironolactone
)
Unlike
Spironolactone
, not associated with
Gynecomastia
Dosing
Released in 2021 at $610/month
Normal
Renal Function
(eGFR >60 ml/min)
Start: 10 to 20 mg orally once daily for 4 weeks, then 20 mg orally daily
Indications to continue at 10 mg dose
Serum Potassium
>4.8 mmol/L
eGFR decreases >30% from baseline
Reduced
Renal Function
(eGFR 25 to 60 ml/min)
Take 10 mg orally once daily
Monitoring
Serum Creatinine
(and eGFR)
Limit to 10 mg/day if eGFR <60 ml/min or eGFR decreases >30% from baseline
Discontinue if eGFR <25 ml/min
Serum Potassium
Obtain baseline, at four weeks and regularly afterward
Hold Finerenone if
Serum Potassium
>5.5 mmol/L
May restart if
Serum Potassium
<5.0 mmol/L
Adverse Effects
Hyperkalemia
(14%)
Hypotension
(4.6%)
Hyponatremia
(1.3%)
Drug Interactions
Medications that raise
Serum Potassium
Finerenone is typically combined with
ACE Inhibitor
s (or ARBs) - monitor
Serum Potassium
Avoid with
NSAID
s
Avoid with
Potassium
supplements
Strong
CYP3A4
inhibitors (increased adverse effects and toxicity)
Itraconazole
Amiodarone
Diltiazem
Ritonavir
Strong
CYP3A4
Inducers (decreased efficacy)
Rifampin
Phenytoin
Carbamazepine
Efavirenz
Safety
Unknown safety in pregnancy
Contraindicated in
Lactation
Resources
Finerenone (DailyMed)
https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=fc726765-5d5a-4d6e-b037-b847bda9fb7c
References
(2021) Presc Lett 28(10): 58-9
Bakris (2020) N Engl J Med 383:2219-29 [PubMed]
Type your search phrase here